PVs in BRCA1 and BRCA2 have implications not only for early detection and risk reduction of several associated cancer types but also have the potential to inform eligibility for PARP inhibitor therapy.39 Similarly, early detection and prevention options are recommended for individuals with PMS2 PVs.40 For individuals with pathogenic ATM variants, increased breast cancer surveillance is recommended.39 The gene discussed is BRCA2; the disease is breast carcinoma.